Critical reviews in oncology/hematology最新文献_第2页

Nature killer cell for solid tumors: Current obstacles and prospective remedies in NK cell therapy and beyond 治疗实体瘤的自然杀伤细胞：NK 细胞疗法及其他疗法目前面临的障碍和未来的补救措施。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-06 DOI: 10.1016/j.critrevonc.2024.104553

Jia-Hao Tao , Jun Zhang , Hua-Shun Li , Yong Zhou , Cha-Xiang Guan

引用次数: 0

BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review BCMA CAR-T诱导浆细胞性淋巴瘤同步转化为慢性淋巴细胞白血病的患者获得完全和持久缓解：病例报告和文献综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-05 DOI: 10.1016/j.critrevonc.2024.104551

Shaomei Feng , Yu Xiong , Weicheng Liu , Haidi Liu , Weiwei Sui , Peihao Zheng , Meiling Sun , Kai Hu , Yajing Zhang

{"title":"BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review","authors":"Shaomei Feng , Yu Xiong , Weicheng Liu , Haidi Liu , Weiwei Sui , Peihao Zheng , Meiling Sun , Kai Hu , Yajing Zhang","doi":"10.1016/j.critrevonc.2024.104551","DOIUrl":"10.1016/j.critrevonc.2024.104551","url":null,"abstract":"<div><div>Richter transformation is still a serious risk in the era of innovative therapies, despite the fact that targeted therapy with Bruton’s tyrosine kinase inhibitor has significantly improved the prognosis for chronic lymphocytic leukemia (CLL). We report a rare case of a 61-year-old male patient’s CLL transforming into a synchronous clonal related plasmablastic lymphoma (PBL) after receiving ibrutinib. During COVID-19, the patient stopped taking ibrutinib, which caused the illness to worsen. Histology revealed that PBL was present in the right supraclavicular mass and that CLL had penetrated the bone marrow. Three cycles of CHP (cyclophosphamide, doxorubicin, and prednisone) were administered together with venetoclax and brentuximab vedotin. After receiving BCMA CAR-T cell treatment, the patient was in complete remission. For PBL transformation, a condition with a worse prognosis and few therapy choices, our results suggest the use of BCMA CAR-T and novel target agents.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104551"},"PeriodicalIF":5.5,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The application of stepped-wedge cluster-randomized controlled trial study designs in oncology settings: A systematic review 阶梯式楔形分组随机对照试验研究设计在肿瘤学环境中的应用：系统综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-01 DOI: 10.1016/j.critrevonc.2024.104547

Hannah Jongebloed , Anna Chapman , Skye Marshall , Liliana Orellana , Victoria White , Patricia Livingston , Anna Ugalde

{"title":"The application of stepped-wedge cluster-randomized controlled trial study designs in oncology settings: A systematic review","authors":"Hannah Jongebloed , Anna Chapman , Skye Marshall , Liliana Orellana , Victoria White , Patricia Livingston , Anna Ugalde","doi":"10.1016/j.critrevonc.2024.104547","DOIUrl":"10.1016/j.critrevonc.2024.104547","url":null,"abstract":"<div><div>Stepped-wedge cluster-randomized trials (SW-CRTs) offer advantages for implementation research in healthcare and have been increasingly utilised in the oncology setting. Cancer-related SW-CRTs need to be robust to deliver impactful trial outcomes and support effective translation into practice. This review aimed to examine the application of the SW-CRT design in oncology settings including the trial design features and protocol deviations, the interventions tested, and the implementation aspects of those interventions. Five databases were searched from database inception to July 2023 for SW-CRTs which evaluated interventions in adults with cancer. Intervention characteristics, design features, protocol deviations, statistical approach, implementation strategies, and outcomes were described and evaluated narratively. The search yielded 3395 unique records with representing 15 trials which are reported over 49 publications. The 15 trials (n = 8 efficacy trials and n = 7 implementation trials) described diverse interventions in healthcare settings. Trials supported implementation of the intervention via educating and training healthcare professionals (n = 12; 80 %), met or exceeded recruitment targets (n = 10, 67 %) and evaluated a new model of care (n = 7; 47 %). Despite implementation outcomes being reported in 14 (93 %) trials, 12 (86 %) did not use an established evaluation framework to guide the selection and reporting of implementation outcomes. SW-CRTs were a utilised design for implementing diverse and complex healthcare interventions in the oncology setting. Trialists should consider the need to incorporate implementation frameworks, strategies and outcomes into their trial planning and resource allocation. This strategic approach can enhance the design and impact of SW-CRTs, leading to improved patient outcomes and advancements in cancer care.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104547"},"PeriodicalIF":5.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adapted physical activity programs for the prevention and treatment of musculoskeletal pain induced by aromatase inhibitors in non-metastatic breast cancer patient: A scoping review 预防和治疗非转移性乳腺癌患者因芳香化酶抑制剂引起的肌肉骨骼疼痛的适应性体育活动计划：范围界定综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-11-01 DOI: 10.1016/j.critrevonc.2024.104548

Nathalie Piazzon , Marion Cortet , Elise Vérot , Florence Carrouel

{"title":"Adapted physical activity programs for the prevention and treatment of musculoskeletal pain induced by aromatase inhibitors in non-metastatic breast cancer patient: A scoping review","authors":"Nathalie Piazzon , Marion Cortet , Elise Vérot , Florence Carrouel","doi":"10.1016/j.critrevonc.2024.104548","DOIUrl":"10.1016/j.critrevonc.2024.104548","url":null,"abstract":"<div><h3>Background</h3><div>Aromatase inhibitor is associated with a high incidence of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in postmenopausal women with hormone-sensitive breast cancer.</div></div><div><h3>Objective</h3><div>This scoping review aims to identify available information regarding the frameworks, models, or strategies of adapted physical activity (APA) programs implemented for the prevention and management of AIMSS.</div></div><div><h3>Methods</h3><div>Search was realized by two independent reviewers in six databases following PRISMA-ScR guidelines. Data of included articles were extracted, and risk of bias analyzed.</div></div><div><h3>Results</h3><div>Finally, 14 were included. No study has examined APA in the prevention of AIMSS. There is no solid evidence supporting the impact of APA on the management of AIMSS. However, evidence suggests that an APA program can reduce the worst joint pain and improve the quality of life.</div></div><div><h3>Conclusion</h3><div>Future research will enlighten clinical practices with the development of personalized APA programs in hormone-sensitive breast cancer.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104548"},"PeriodicalIF":5.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review 奥希替尼加脑放疗与奥希替尼单药治疗在表皮生长因子受体突变非小细胞肺癌脑转移中的作用：一项荟萃分析和系统综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-10-30 DOI: 10.1016/j.critrevonc.2024.104540

Alessandro Nepote , Stefano Poletto , Valentina Bertaglia , Simona Carnio , Carlo Piumatti , Cristina Lanzetta , Ornella Cantale , Giorgio Saba , Paolo Bironzo , Silvia Novello , Antonino Carmelo Tralongo

{"title":"Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated non-small-cell lung cancer with brain metastases: A meta-analysis and systematic review","authors":"Alessandro Nepote , Stefano Poletto , Valentina Bertaglia , Simona Carnio , Carlo Piumatti , Cristina Lanzetta , Ornella Cantale , Giorgio Saba , Paolo Bironzo , Silvia Novello , Antonino Carmelo Tralongo","doi":"10.1016/j.critrevonc.2024.104540","DOIUrl":"10.1016/j.critrevonc.2024.104540","url":null,"abstract":"<div><div>Single-agent osimertinib has improved outcomes in EGFR-mutated lung cancer patients with brain metastases (BMs), but still, 40 % of them will experience an intracranial progression. We performed a systematic review to evaluate the role of brain radiotherapy upfront plus osimertinib. We evaluated articles comparing the use of osimertinib versus osimertinib plus brain radiotherapy. We included 897 patients from nine retrospective studies. Patients treated with combination therapy had an improvement in intracranial progression-free survival (HR 0.76; 95 % CI 0.61–0.94) and overall survival (HR 0.56; 95 % CI 0.36–0.87) with an acceptable safety profile. Osimertinib with upfront brain radiotherapy may be a suitable first-line treatment option for EGFR mutated patients with BMs at diagnosis. The main limitations of this analysis are the retrospective nature and the inability to control for a single variable of interest. Despite that, the combination of osimertinib and upfront brain radiotherapy is a treatment strategy that deserves further prospective trials.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"205 ","pages":"Article 104540"},"PeriodicalIF":5.5,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The integration of radiotherapy with systemic therapy in advanced triple-negative breast cancer 晚期三阴性乳腺癌放疗与系统疗法的整合。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-10-29 DOI: 10.1016/j.critrevonc.2024.104546

Fang Yang

{"title":"The integration of radiotherapy with systemic therapy in advanced triple-negative breast cancer","authors":"Fang Yang","doi":"10.1016/j.critrevonc.2024.104546","DOIUrl":"10.1016/j.critrevonc.2024.104546","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with high aggressiveness and poor prognosis. For patients who have undergone multiple treatments, systemic drug therapy often presents challenges with limited efficacy and significant side effects. Radiotherapy, a pivotal local treatment, has shown substantial local control benefits in patients with inoperable locally advanced or metastatic disease. Clinical evidence suggests that integrating systemic therapy with locoregional radiotherapy can confer survival advantages in advanced malignancies. Within multidisciplinary treatment, the synergy between radiotherapy and systemic therapies shows promise for enhancing outcomes and extending survival. This review synthesizes recent advances in combining radiotherapy and systemic therapy in managing advanced TNBC, focusing on preclinical and clinical evidence regarding efficacy and safety. By reviewing these advancements, we aim to identify novel therapeutic strategies and integrate clinical evidence to inform best practices in TNBC management, ultimately improving patient outcomes.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104546"},"PeriodicalIF":5.5,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating the role of the intratumoral microbiome in thyroid cancer development and progression 研究瘤内微生物组在甲状腺癌发展和恶化中的作用

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-10-28 DOI: 10.1016/j.critrevonc.2024.104545

Hanieh Ataollahi , Mehdi Hedayati , Noosha Zia-Jahromi , Maryam Daneshpour , Seyed Davar Siadat

引用次数: 0

Origin, development and therapy of colorectal cancer from the perspective of a biologist and an oncologist 从生物学家和肿瘤学家的角度看结直肠癌的起源、发展和治疗

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-10-25 DOI: 10.1016/j.critrevonc.2024.104544

Jiri Svec , Jakub Onhajzer , Vladimir Korinek

引用次数: 0

The role of hyperthermia in the treatment of tumor 热疗在治疗肿瘤中的作用。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-10-24 DOI: 10.1016/j.critrevonc.2024.104541

Weiwei Zhu , Siwei Pan , Jiaqing Zhang , Jingli Xu , Ruolan Zhang , Yanqiang Zhang , Zhenjie Fu , Yuqi Wang , Can Hu , Zhiyuan Xu

{"title":"The role of hyperthermia in the treatment of tumor","authors":"Weiwei Zhu , Siwei Pan , Jiaqing Zhang , Jingli Xu , Ruolan Zhang , Yanqiang Zhang , Zhenjie Fu , Yuqi Wang , Can Hu , Zhiyuan Xu","doi":"10.1016/j.critrevonc.2024.104541","DOIUrl":"10.1016/j.critrevonc.2024.104541","url":null,"abstract":"<div><div>Despite recent advancements in the diagnosis and treatment options for cancer, it remains one of the most serious threats to health. Hyperthermia (HT) has emerged as a highly promising area of research due to its safety and cost-effectiveness. Currently, based on temperature, HT can be categorized into thermal ablation and mild hyperthermia. Thermal ablation involves raising the temperature within the tumor to over 60°C, resulting in direct necrosis in the central region of the tumor. In contrast, mild hyperthermia operates at relatively lower temperatures, typically in the range of 41–45°C, to induce damage to tumor cells. Furthermore, HT also serves as an immune adjuvant strategy in radiotherapy, chemotherapy, and immunotherapy, enhancing the effectiveness of radiotherapy, increasing the uptake of chemotherapy drugs, and reprogramming the tumor microenvironment through the induction of immunogenic cell death, thereby promoting the recruitment of endogenous immune cells. This article reviews the current status and development of hyperthermia, outlines potential mechanisms by which hyperthermia inhibits tumors, describes clinical trial attempts combining hyperthermia with radiotherapy, chemotherapy, and immunotherapy, and discusses the relationship between nanoparticles and hyperthermia.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104541"},"PeriodicalIF":5.5,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142514706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dysregulation of systemic immunity in colorectal cancer and its clinical applications as biomarkers and therapeutics 结直肠癌的全身免疫失调及其作为生物标记物和疗法的临床应用。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-10-24 DOI: 10.1016/j.critrevonc.2024.104543

Changqin Li , Jian Li

引用次数: 0